Highlights Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Real-time Estimate Cboe BZX Other stock markets 20:11:25 26/06/2024 BST			5-day change	1st Jan Change
3.235 ^USD	-2.27%		-2.11%	+22.26%

06-17	Design Therapeutics, Inc. Elects Pratik Shah, Ph.D. as Class III Director	CI
05-08	Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sector Update: Health Care Stocks Ease Late Afternoon	03-20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	03-20	MT
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	03-20	MT
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Design Therapeutics, Inc. Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia	14/08/23	CI
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Design Therapeutics, Inc. to Present Preclinical Data on its GeneTAC(TM) Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023	24/04/23	CI
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/03/23	CI
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	14/03/23	CI
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	14/03/23	CI
Design Therapeutics, Inc. Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress	07/12/22	CI
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Design Therapeutics, Inc. to Present Preclinical Data Highlighting the Potential of its GeneTAC(TM) Small Molecule, DT-216, for the Treatment of Friedreich Ataxia	17/10/22	CI
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	08/08/22	CI
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	09/05/22	CI
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of Dt-216 Genetac™ Molecule for the Treatment of Friedreich Ataxia	30/03/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Highlights

Filters